NF-kappa B Inhibitors – Pipeline Insight, 2020
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “NF-kappa B Inhibitors – Pipeline Insight, 2020,” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
NF-kappa B Inhibitors: Overview
The nuclear factor-?B (NF-?B) signaling pathway plays a major role in the development, maintenance, and progression of most chronic diseases. NF-?B controls the expression of genes involved in a number of physiological responses, including immune inflammatory responses, acute-phase inflammatory responses, oxidative stress responses, cell adhesion, differentiation, and apoptosis. Recent studies have suggested that NF-?B dysregulation is associated with many diseases including AIDS, atherosclerosis, asthma, arthritis, diabetes, inflammatory bowel disease, stroke, muscle wasting and viral infections. Mounting evidence indicates that NF-kB acts as a link between inflammation and cancer progression, making NF-?B essential to and a potential drug target in hematological malignancies and solid tumors. NF-?B was first identified in 1986 by Sen and Baltimore in the nucleus bound to an enhancer element of the immunoglobulin kappa light chain gene in B cells. It is now known to be ubiquitous in nature present in all the cell types and is evolutionary conserved. It belongs to the family of Rel proteins that includes c-Rel, RelA (p65), RelB, NF-?B1 (p50 and its precursor p105), and NF-?B2 (p52 and its precursor p100) all of which can form hetero- or homodimers.
NF-kappa B Inhibitors Emerging Drugs Chapters
This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NF-kappa B Inhibitors Emerging Drugs
Further product details are provided in the report……..
NF-kappa B Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
NF-kappa B Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.
Report Highlights
DelveInsight’s, “NF-kappa B Inhibitors – Pipeline Insight, 2020,” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
NF-kappa B Inhibitors: Overview
The nuclear factor-?B (NF-?B) signaling pathway plays a major role in the development, maintenance, and progression of most chronic diseases. NF-?B controls the expression of genes involved in a number of physiological responses, including immune inflammatory responses, acute-phase inflammatory responses, oxidative stress responses, cell adhesion, differentiation, and apoptosis. Recent studies have suggested that NF-?B dysregulation is associated with many diseases including AIDS, atherosclerosis, asthma, arthritis, diabetes, inflammatory bowel disease, stroke, muscle wasting and viral infections. Mounting evidence indicates that NF-kB acts as a link between inflammation and cancer progression, making NF-?B essential to and a potential drug target in hematological malignancies and solid tumors. NF-?B was first identified in 1986 by Sen and Baltimore in the nucleus bound to an enhancer element of the immunoglobulin kappa light chain gene in B cells. It is now known to be ubiquitous in nature present in all the cell types and is evolutionary conserved. It belongs to the family of Rel proteins that includes c-Rel, RelA (p65), RelB, NF-?B1 (p50 and its precursor p105), and NF-?B2 (p52 and its precursor p100) all of which can form hetero- or homodimers.
NF-kappa B Inhibitors Emerging Drugs Chapters
This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NF-kappa B Inhibitors Emerging Drugs
- AMG 0101: AnGes MG
- CXA-10: Complexa
- Upregulation of Nrf2 pathways, a key pro-reparative and metabolic pathway
- Inhibition of NF-Kappa B and TLR4, key drivers of inflammatory molecules and pathways
- Inhibition of Xanthine Oxidoreductase, a key intracellular producer of Reactive Oxygen Species add that result in cellular oxidative stress
- Increasing the expression of heat shock proteins, which act as chaperones during cellular stress to restore cellular homeostatic mechanisms
- ACT001: Accendatech
Further product details are provided in the report……..
NF-kappa B Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in NF-kappa B Inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
NF-kappa B Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence NF-kappa B Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- In October 2020, Catabasis has stopped development of edasalonexent as phase III PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo.
- In October 2019, The Company’s lead candidate, CXA-10, received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).
- NF-kappa B Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- What are the current treatment options available based on the NF-kappa B Inhibitors?
- How many companies are developing therapies by working on NF-kappa B Inhibitors?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for NF-kappa B Inhibitors to treat disease condition?
- How many emerging therapies are in early-stage, mid-stage, and late stage of development for NF-kappa B Inhibitors?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NF-kappa B Inhibitors therapies?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies developed based on this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for NF-kappa B Inhibitors and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for NF-kappa B Inhibitors?
- How many patents are granted and pending for the emerging therapies of NF-kappa B Inhibitors?
- AnGes MG
- Complexa
- Accendatech
- Serenex
- OncoViRx
- Novo Nordisk
- Profectus Biosciences
- Mitsubishi Tanabe Pharma
- ImmuneTarget
- Merck Serono
- EntreChem
- Link Health Group
- AMG 0101
- CXA-10
- ACT001
- Research programme: NF-kappa B inhibitors
- Research programme: I-kappa B kinase/NF-kappa B inhibitors
- Research programme: NF-kappa-B pathway inhibitors
- IT 901
- AS 602868
- EC 70124
- LH 025
Introduction
Executive Summary
NF-kappa B Inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NF-kappa B Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NF-kappa B Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NF-kappa B Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AMG 0101: AnGes MG
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
CXA-10: Complexa
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ACT001: Accendatech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
NF-kappa B Inhibitors Key Companies
NF-kappa B Inhibitors Key Products
NF-kappa B Inhibitors- Unmet Needs
NF-kappa B Inhibitors- Market Drivers and Barriers
NF-kappa B Inhibitors- Future Perspectives and Conclusion
NF-kappa B Inhibitors Analyst Views
NF-kappa B Inhibitors Key Companies
Appendix
Executive Summary
NF-kappa B Inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
NF-kappa B Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NF-kappa B Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NF-kappa B Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AMG 0101: AnGes MG
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
CXA-10: Complexa
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ACT001: Accendatech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
NF-kappa B Inhibitors Key Companies
NF-kappa B Inhibitors Key Products
NF-kappa B Inhibitors- Unmet Needs
NF-kappa B Inhibitors- Market Drivers and Barriers
NF-kappa B Inhibitors- Future Perspectives and Conclusion
NF-kappa B Inhibitors Analyst Views
NF-kappa B Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for NF-kappa B Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for NF-kappa B Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for NF-kappa B Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for NF-kappa B Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
